Cancer statistics, 2013
By R. Siegel, D. Naishadham, A. Jemal. Ca, 2013
11,779 citations recorded by the source corpus.
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. A total of 1,660,290 new cancer cases and 580,350 cancer deaths are projected to occur in the United States in 2013. During the most recent 5 years for which there are data (2005‐2009), delay‐adjusted cancer incidence rates declined slightly in men (by 0.6% per year) and were stable in women, while cancer death rates decreased by 1.8% per year in men and by 1.5% per year in women. Overall, cancer death rates have declined 20% from their peak in 1991 (215.1 per 100,000 population) to 2009 (173.1 per 100,000 population). Death rates continue to decline for all 4 major cancer sites (lung, colorectum, breast, and prostate). Over the past 10 years of data (2000‐2009), the largest annual declines in death rates were for chronic myeloid leukemia (8.4%), cancers of the stomach (3.1%) and colorectum (3.0%), and non‐Hodgkin lymphoma (3.0%). The reduction in overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of approximately 1.18 million deaths from cancer, with 152,900 of these deaths averted in 2009 alone. Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population, with an emphasis on those groups in the lowest socioeconomic bracket and other underserved populations. CA Cancer J Clin 2013;. © 2013 American Cancer Society.
Subfields: Economics and Econometrics, Oncology
View Paper: https://www.semanticscholar.org/paper/c520dcd646e110218107a6276be0a153ae81b8be
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Economics and Econometrics
In Oncology
- Hans Clevers
- N. Nagarsheth
- Peter L. Choyke
- W. Zou
- Ronald M. Summers
- Giulia Biffi
- D. Tuveson
- Shijun Wang
Citations in the corpus
- Chronic Inflammation and Cytokines in the Tumor Microenvironment (2014, background): “A mortality rate of about 9% has been reported for both men and women, with 5-year survival between 74% and 59% for early stages (stages I to IIC) and 6% for stage IV [178].”
- Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. (2013, neutral): “Given that the majority of the nearly 2 million patients diagnosed with cancer in 2012 in the United States alone underwent at least one surgical procedure, the tremendous potential burden of infection becomes apparent (18).”
- Automated diagnosis of prostate cancer in multi-parametric MRI based on multimodal convolutional neural networks (2017, background): “Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the second leading cause of cancer death among men (Chou et al 2011, Siegel et al 2012, 2013).”
- Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2014, background): “Mortality due to pancreatic cancer is projected to surpass that of breast and colorectal cancer by 2030 in the United States (Rahib et al., 2014; Siegel et al., 2013).”
- Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment (2018, background): “Cancer is one of the leading causes of morbidity and mortality worldwide with about 20% of all deaths in developed countries [1].”
- Computer Aided-Diagnosis of Prostate Cancer on Multiparametric MRI: A Technical Review of Current Research (2014, background): “Twenty-eight percent of cancers inmen occur in the prostate, making prostate cancer (PCa) and its detection a priority in cancer research [1].”